Mark A Richardson

Title: Mark A Richardson: Innovator in Antibiotic Production

Introduction

Mark A Richardson is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of antibiotic production, holding a total of 6 patents. His work focuses on innovative methods for transforming actinomycetes and enhancing the production of antibiotics.

Latest Patents

One of his latest patents is titled "Use of the site-specific integrating function of phage .phi.C31." This invention provides a method for transforming an actinomycete with an integrating vector, which boasts high transformation rates, site-specific integration, and stable maintenance without antibiotic selection. Additionally, it includes methods for increasing antibiotic production and creating hybrid antibiotics. Another notable patent is "Macrolide biosynthetic genes for use in streptomyces and other organisms." This invention offers spiramycin antibiotic biosynthetic genes from Streptomyces ambofaciens, along with various recombinant DNA vectors. These genes can enhance or modify the macrolide antibiotic-producing capabilities of organisms, leading to the generation of novel antibiotics.

Career Highlights

Mark A Richardson is currently employed at Eli Lilly and Company, where he continues to advance research in antibiotic development. His innovative approaches have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Throughout his career, he has collaborated with notable colleagues, including Jeffrey T Fayerman and Karen L Cox. These partnerships have contributed to the success of his research and patent developments.

Conclusion

Mark A Richardson's work in antibiotic production exemplifies the impact of innovation in the pharmaceutical field. His patents reflect a commitment to advancing medical science and improving health outcomes.